Prospective, open-label, single arm, multicenter, pharmacokinetic, and safety study of a single dose intravenous human plasma-derived C1 Esterase Inhibitor (C1-INH) concentrate in patients with congenital C1-INH deficiency and hereditary angioedema
Latest Information Update: 12 Jan 2022
Price :
$35 *
At a glance
- Drugs Complement C1 inhibitor protein (Primary)
- Indications Hereditary angioedema
- Focus Pharmacokinetics
- Acronyms CONE-01
- Sponsors Octapharma
- 09 Mar 2021 Status changed from active, no longer recruiting to completed.
- 09 Feb 2021 Status changed from recruiting to active, no longer recruiting.
- 08 Apr 2020 Status changed from recruiting to suspended.